Yumuşak,. İ.G.; Yıldırım, D. Ç. Sağlık Harcamaları İktisadi Büyüme İlişkisi Üzerine Ekonometrik Bir İnceleme. Bilgi Ekonomisi ve Yönetimi Dergisi 2009, 4(1), 57-70.
Mutlu, A. ; Işık, A. Sağlık Ekonomisine Giriş. Ekin Yayınları: Bursa, Türkiye, 2005, ISBN 9786055335991
Bölükbaşı, N.; Işık, H.; Söyler, S. OECD Ülkelerinde İlaç Harcamaları ile Sağlık Harcamaları. Hekim ve Hemşirelik Mezunları Arasındaki İlişkilerin İncelenmesi. Ekonomi İşletme Siyaset ve Uluslararası İlişkiler Dergisi (JEBPIR). 2020, 6, 223-231.
Wainwright, D. The Changing Face of Medical Sociology. A Sociology of Health. SAGE Publications: London, United Kingdom, 2008, ISBN 9781412921589
DOI: https://doi.org/10.4135/9781446213575
Özdemir, B. Türkiye'de İlaç Pazarının Analizi ve Ekonomi Üzerine Etkisi. Niğde: Niğde Ömer Halisdemir Üniversitesi. Sosyal Bilimler Enstitüsü. Türkiye, 2019.
Mikulic, M. Global Pharmaceutical Industry - Statistics & Facts. Available online: https://www.statista.com/topics/1764/global-pharmaceutical-industry/#topicOverview. (Date of Access: 2024-01-15)
Zhang, W. Pharmaceutical industry in China - statistics & facts. Available online: https://www.statista.com/topics/5001/pharmaceutical-industry-in-china/#topicOverview. (Date of Access: 2024-01-01)
Salib, V. Comparing Global Pharmaceutical Markets: US. UK. and China. Pharmanews Intelligence 07.02.2023. Available online: https://pharmanewsintel.com/features/comparing-global-pharmaceutical-markets-the-us-uk-and-china. (Date of Access: 2023-12-18)
Hernandez, I.; San-Juan-Rodriguez, A; Good, C. B.; Gellad, W. F. Changes in List Prices. Net Prices and Discounts for Branded Drugs in the US, 2007–2018. JAMA 2020, 323(9), 854-862. DOI: 10.1001/jama.2020.1012
DOI: https://doi.org/10.1001/jama.2020.1012
Kapczynski, A. The Political Economy of Market Power in Pharmaceuticals. J. Health Polit. Policy Law. 2023, 48(2), 215-239. DOI: 10.1215/03616878-10234184
DOI: https://doi.org/10.1215/03616878-10234184
Gostin, L. O. Biden’s Plan to Vaccinate the World Won’t Work. Here’s a Better One. Washington Post. 27. 09. 2021. Available online: https://www.washingtonpost.com/outlook/2021/09/27/biden-vaccines-globe-inequity-donations/.[Date of Access: 2023-12-30]
Vogler, S.; Habl, C; Leopold, C; Mazag, J,; Morak, S.; Zimmerman, N. PHIS Pharmaceutical Health Information system. Hospital Pharma Report 2010. 05 .2010. Available online: https://webgate.ec.europa.eu/chafea_pdb/assets/files/pdb/2007333/2007333_phis_hospital_pharma_rep. (Date of Access: 2024-01-01).
Carone, G.; Schwierz, C.; Xavier, A. Cost-containment Policies in Public Pharmaceutical Spending in the EU. Economic Papers 2012, 461. Available online: https://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf.(Date of Access:2024-01-01)
DOI: https://doi.org/10.2139/ssrn.2161803
Kanavos, P.; Seeley, L.; Vandoros, S. Tender Systems for Outpatient Pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. 10.2009. Available online: https://www.politico.eu/wp-content/uploads/2019/02/Tender-systems-for-outpatient-pharmaceuticals-in-the-EU.pdf. [Date of Access: 2024-01-01]
Garcia-Goni, M. Rationalizing Pharmaceutical Spending. 2022. Available online: https://www.elibrary.imf.org/view/journals/001/2022/190/article-A001-en.xml?ArticleTabs=fulltext. eISBN: 9798400219849 [Date of Access: 2024-01-01]
DOI: https://doi.org/10.5089/9798400219849.001
Danzon, P. M.; Mulcahy, A. W. ; Towse, A. K. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition. and Procurement. Health Economics 2015, 24(2), 238-252. DOI: 10.1002/hec.3013
DOI: https://doi.org/10.1002/hec.3013
Wirtz, V. J.; Hogerzeil, H. V.; Gray, A. L.; Bigdeli, M.; De Joncheere, C. P.; Ewen, M. A. Essential Medicines for Universal Health Coverage. The Lancet 2017, 389(10067), 403-476.
DOI: https://doi.org/10.1016/S0140-6736(16)31599-9
Bonnifield, R. S.; Keller, J. M.; Glasman, A.; Chalkidaou, K. Tackling the Triple Transition in Global Health Procurement. Center for Global Development Reports 2019. Available online: https://www.cgdev.org/better-health-procurement (Date of Access: 2024-01-01]
Kaplan, A. W.; Ritz, L. S.; Vitello, M.; Wirtz, V. J. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 2012, 106(3), 211-224. DOİ: 10.1016/j.healthpol.2012.04.015
DOI: https://doi.org/10.1016/j.healthpol.2012.04.015
Hoen, E. The global politics of pharmaceutical monopoly power. Drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and Public Health. AMB Publishers, Diemen, The Netherlands, 2009. ISBN 97890 79700 06 6
Kesselheim, A. S.; Avorn, J.; Sarpatwari, A. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA, 2016, 316(8), 858-871. DOİ: 10.1001/jama.2016.11237
DOI: https://doi.org/10.1001/jama.2016.11237
Mulcahy, A. W.; Whaley, C. M.; Gizaw, M.; Schwam, D.; Edenfield, N.; Becerra-Ornelas, A. U.International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies. RAND Corporation: Research Report 2021. DOI: https://doi.org/10.7249/RR2956. Available online: https://www.rand.org/pubs/research_reports/RR2956.html. (Date of Access:2023-12-29)
IMF. World Economic Outlook Slowing Growth, Rising Risks. (September 2011). Washington. Available online: https://www.imf.org/en/Publications/WEO/Issues/2016/12/31/Slowing-Growth-Rising-Risks. (Date of Access: 2023-12-16).
OECD.Stat. Available online: https://stats.oecd.org/index.aspx?r=756968&lastaction=login_submit#. (Date of Access: 2023-12-26).